The design of "REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC" has been published. Notably, the first author is John Heymach, a world-renowned leader in NSCLC with EGFR mutations. https://www.tandfonline.com/doi/full/10.1080/14796694.2025.2457294
Market Data 
Markets 
AI
